Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK of Zibotentan/Dapagliflozin FDC in Healthy Participants
NCT07404137Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zibotentan and dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 1 more. Started Feb 2026; status: completed.
02
Drugs
zibotentandapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07404137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404137.